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3. ABBREVIATIONS 
AC   adjuvant chemotherapy  
AP-2 proteins Activator protein-2, family of transcriptions factors 
BOT   borderline ovarian tumor  
BRAF  v-raf murine sarcoma viral oncogen homolog B1 
BRCA  breast and ovarian cancer locus  
CA 125  cancer antigen 125 
CK (7 and 20) cytokeratin 7 and 20 
c-kit   one of the tyrosine kinase receptors 
CRP   C-reactive protein  
DAB  diaminobenzidine terahydrochloride 
ECM   extracellular matrix  
EDTA   ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay  
Eng   endoglin (also named CD 105) 
ERK   extra-cellular regulated kinase 
FIGO  International Federation of Gynaecology and Obstetrics
GOG   Gynecologic Oncology Group  
HNPCC  hereditary nonpolyposis colorectal cancer syndrome  
HRAS  Harvay RAS 
ICON   International Collaborative Ovarian Neoplasm 
IHC   immunohistochemistry  
JNK   c-jun amino-terminal kinase 
kDa   kilo Dalton  
KRAS  Kirsten RAS
MAPK  mitogen activated protein kinase 
MMP   matrix metalloproteinases  
MPSC  micropapillary serous carcinoma  
MVD   microvessel density  
mRNA  messenger ribonucleic acid 
NGF   nerve growth factor 
NRAS  neuroblastoma RAS 
(PI3K)/AKT  the phosphoinositol-3-kinas/AKT pathway 
P38   high-osmolarity glycerol response kinase  
PMP  pseudomyxoma peritonei   
PTEN   phosphatase and tensin homolog deleted from chromosome 10 
RAS   family of cellular oncogenes  
RMI   risk for malignancy index  
RT-PCR  reverse transciptase polymerase chain reaction 
SEng   soluble endoglin  
SBT   serous borderline tumor 
TGF  transforming growth factor 
TMV   tissue microarray  
TrkA  tropomyosin receptor kinase A  
USO   unilateral salphingo-oophorectomy  
WHO   World Health Organization  
VEGF-A vascular endothelial growth factor A 
vWF   von Willebrand factor  
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4. INTRODUCTION 
4.1 Cancer: uncontrolled cell growth  
Cancer is a disease of uncontrolled cell growth. Cancer results from a series of acquired 
defects in the DNA that cause deregulation of the cell’s growth processes. The damaged cell 
transforms from benign to malignant and becomes independent of normal regulatory 
signals. This transformed cell multiplies into a clone of malignant cells, eventually 
developing into a tumor (1). The malignant tumor infiltrates adjacent tissues and 
metastasizes. Cancer is a multi-step process, involving the progressive loss of control by the 
mutated cell with failure of DNA repair systems. Local invasion and distant metastasis are 
the main factors responsible for cancer-related morbidity and mortality. Both processes are 
functions of the complex interactions between tumor cells and the surrounding stroma, 
which are mediated by the production of a wide variety of molecules, among which matrix-
degrading proteases, growth factors, adhesion molecules and angiogenic factors play a 
central role (2;3). Hanahan and Weinberg have summarized six essential acquired functional 
capabilities of cancer cells that drive the malignant growth, including self-sufficiency in 
growth signals, insensitiveness to anti-growth signals, capability to evade apoptosis 
(programmed cell death), limitless replication potential, capability to sustain angiogenesis, 
as well as capability to invade and metastasize (4). Metastatic disease is the cause of 90% of 
human cancer deaths (5).     
4.2 Tumors of the ovary 
4.2.1 Histological classification of epithelial tumors of the ovary 
Neoplasms of surface epithelial origin account for about 65-70% of all primary ovarian 
tumors, but 90% of all malignant ovarian tumors (6). Epithelial tumors of the ovary are sub-
classified according to morphology by WHO (World Health Organization) Classification of 
Tumors 2003 (7): 
A. Serous tumors
Benign (cystadenoma, surface papilloma, adenofibroma) 
Borderline tumor (papillary cystic tumor, surface papillary tumor, adenofibroma) 
Malignant (adenocarcinoma, surface papillary adenocarcinoma, adenocarcinofibroma) 
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B. Mucinous tumors
Benign (cystadenoma, adenofibroma, cystadenofibroma) 
Borderline tumor (intestinal type, endocervical like type)
Malignant (adenocarcinoma, surface papillary adenocarcinoma) 
C. Endometrioid tumors including variants with squamous differentiation
Benign (cystadenoma, adenofibroma and cystadenofibroma) 
Borderline tumor (cystic tumor, adenofibroma and cystadenofibroma) 
Malignant (adenocarcinoma, adenocarcinofibroma, malignant mullerian mixed tumor, 
adenosarcoma, endometrioid stromal sarcoma, undifferentiated ovarian sarcoma) 
D. Clear cell tumors
Benign (cystadenoma, adenofibroma) 
Borderline tumor (cystic tumor, adenofibroma and cystadenofibroma) 
Malignant (adenocarcinoma, adenocarcinofibroma)  
E. Transitional cell tumors  
Benign (Brenner tumor, metaplastic variant) 
Borderline tumor (borderline Brenner tumor, proliferative variant) 
Malignant (transitional cell carcinoma, malignant Brenner tumor) 
F.  Squamous cell tumors  
Malignant (squamous cell carcinoma)  
G. Mixed epithelial tumors  
Benign
Borderline tumor
Malignant
H. Undifferentiated and unclassified tumors 
Malignant (undifferentiated carcinomas, adenocarcinomas not otherwise specified)   
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4.2.2 Clinical staging, incidence and prognosis of ovarian cancer 
Staging system of ovarian cancer according to FIGO (7)
Stage I: Tumor limited to the ovary
Stage IA: Tumor limited to one ovary, capsule intact, no tumor on the ovarian surface, no 
malignant cells in ascites or peritoneal washing 
Stage 1B: Tumor limited to both ovaries, capsules intact, no tumor on the ovarian surface, 
no malignant cells in ascites or peritoneal washing
Stage IC: Tumor limited to one or both ovaries, with any of the following: capsule ruptured, 
tumor on the ovarian surface, malignant cells in ascites or peritoneal washings  
Stage II: Tumor involves one or both ovaries with pelvic extension
Stage IIA: Extension and/or implants on uterus and/or tube(s), no malignant cells in ascites 
or peritoneal washings 
Stage IIB: Extension to other pelvic tissues, no malignant cells in ascites or peritoneal 
washings
Stage IIC: Pelvic extension (IIA and IIB) with malignant cells in ascites or peritoneal 
washings
Stage III: Tumor involves one or both ovaries, with histologically confirmed peritoneal 
metastasis outside the pelvis and/or regional lymph node metastasis
Stage IIIA: Microscopic peritoneal metastasis beyond pelvis 
Stage IIIB: Macroscopic peritoneal metastasis beyond the pelvis, 2 cm or less in greatest 
dimension 
Stage IIIC: Peritoneal metastasis beyond the pelvis, more than 2 cm in greatest dimension 
and/or regional lymph node metastasis 
Stage IV: Distant metastasis (excludes peritoneal metastasis). Pleural effusion must have 
positive cytology for stage IV  
Note: Liver capsule metastasis is stage III, parenchymal liver metastasis equals stage IV  
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Clinical prognosis of ovarian cancer  
Epithelial ovarian cancer is the leading cause of death from gynecological cancer in Western 
countries (8). Survival of ovarian cancer is closely related to the clinical stage at diagnosis 
(Figure 1). The incidence of ovarian cancer varies across nations, race and age. The highest 
incidence rates are reported from Northwestern Europe and North America, where the rates 
have remained almost constant over the last two to three decades (8). In Norway the 
incidence rate (average from 1996 to 2005) for ovarian cancer is 12.5 per 100.000 person-
years (9). The incidence rate for borderline ovarian tumors (BOT) is 4.8 new cases per 
100.000 (average 1995 to 2004) (10). Ovarian epithelial cancer has few early disease 
symptoms, most of the carcinomas (70%) are diagnosed when the disease is in advanced 
stage (8). The Cancer Registry of Norway has followed the survival rate for patients with 
borderline tumors only in recent years (Figure 2). Trimble et al. reported in a population-
based study from USA (1988 to 1997), that 82% of the patients with BOT were in FIGO 
stage I, the 5 years relative survival was 99% (all stages) and that the 10-year relative 
survival was 95% (all stages). A study by Bjørge et al. (11) from Norway (1970 to 1993) 
found the age-adjusted 5-year survival rate for BOT (all stages) to be 93%. Seidman and 
Kurman summarized 97 reports, including a total of 4.129 women with serous BOT tumors, 
and showed a disease-specific survival rate of 99.5% (mean follow-up of 7 years) for stage I 
disease and 95.3% for stage III disease (12). Women with BOT are approximately 10 to 15 
years younger than women with invasive epithelial ovarian cancer (13).
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Figure 1: 1-5 years survival by stage, for women in Norway with invasive epithelial 
ovarian cancer diagnosed from 1995 to 1999 (Data from The Cancer Registry of 
Norway (10)). Red line shows the total survival, all stages. 
Figure 2: 1-5 year survival rate by stage, for women in Norway with BOT diagnosed 
from 1996 to 2000 (Figure by Elin Ødegaard, based on data from The Cancer Registry 
of Norway). BOT is associated with much better prognosis compared to invasive 
ovarian cancer. Red line shows the total survival, all stages. 
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4.2.3 Borderline ovarian tumors (BOT) versus invasive carcinoma 
Borderline ovarian tumors (BOT) versus invasive carcinoma of the ovary borderline ovarian 
tumors, also named tumors of low malignant potential, are distinct from invasive ovarian 
malignancy. BOTs have a much better prognosis (Figure 1 and 2). Histologically, BOTs are 
characterized by epithelial hyperplasia and nuclear atypia, as well as by variable and usually 
minimal mitotic activity, and no destructive stromal invasion (7;14). As described in 4.2.1, 
BOTs can be divided histologically as serous (50%), mucinous (46%), or mixed, 
endometrioid, clear cell or Brenner tumors (the last 4 groups comprising 4% of BOTs) (15).   
Serous borderline
There is a very high incidence of bilaterality in serous BOT (26-66%) (16).
Microinvasion
Although evidence of stromal invasion negate a diagnosis of borderline malignancy there 
have, nevertheless, been several reports of “microinvasion” (defined as one or more foci, 
and none exceeding more than 10mm2, (7)) of the stroma of both serous and mucinous 
tumors which otherwise showed the typical features of neoplasm of borderline malignancy 
(16). Such neoplasms follow the same clinical course and have the same prognosis as 
borderline ovarian tumors without microinvasion (16). Conceptually, neoplasms with 
microinvasion are not of borderline malignancy but clinically they are not adenocarcinomas 
(16), and when the foci of microinvasion is less than 10mm2, they are classified as BOT (7).
Micropapillary pattern
Serous borderline tumors may have two distinct different histological patterns in the same 
neoplasm. Tumors with micropapillary growth pattern (defined as foci <5mm, (17)) present 
more frequently as bilateral tumors and are more often associated with peritoneal implants 
than typical serous BOT (12;18-21). The presence of a significant micropapillary 
component in a BOT therefore needs to be specified in the pathology report (22). Some 
authors have proposed that this pattern of growth should be designated “micropapillary 
serous carcinoma” (MPSC) (17), because of its frequent association with aggressive 
behavior, but others do not share this view and prefer the designation serous borderline 
tumor (SBT) with micropapillary pattern (19-21). Micropapillary tumors behave 
aggressively if they are associated with invasive implants (19). 
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Invasive/ noninvasive implants
There has been, over the years, much argument as to whether the extraovarian lesions 
represent true metastases or whether they are independent of the ovarian neoplasm and 
develop in situ within the secondary Mullerian system, i.e. the submesothelial connective 
tissue (16). Morice et al. evaluated 80 patients with advanced serous BOT and concluded 
that the only prognostic factor for evolution to invasive disease was the type of peritoneal 
implants; 31% of patients with invasive implants developed invasive disease in a 5-year 
period, as compared to only 2% of patients with non-invasive implants (23). Non-invasive 
implants have almost no negative influence on the 10-year survival. The invasive implants 
are associated with a poor prognosis: more than 50% are associated with recurrence, and the 
10-year survival rate is only about 35%. Invasive implants are usually localized in the 
omentum, and the tumor DNA ploidy is often aneuploid (7).    
Mucinous borderline tumors  
Two quite different types of mucinous BOT exist; the mucinous epithelium can be of 
gastrointestinal or of endocervical type (85% vs 15% of mucinous BOTs) (14). 
Pseudomyxoma peritonei (PMP) is a clinical term used to describe the finding of abundant 
gelatinous or mucoid material surrounded by fibrous tissue in the abdominal cavity (14). In 
patients with a mucinous BOT and PMP, the appendix is also involved in 60% of the cases 
(24;25). More than 80% of invasive mucinous carcinomas have components of mucinous 
borderline tumors and mucinous cystadenoma or both, suggesting a progression from 
benign to malignant neoplasia (14), a hypothesis supported by recent molecular studies (26-
28). The majority of investigators believe that mucinous ovarian tumor(s) in patients with 
PMP are metastases from intestinal tumors where the primary tumor is most often located in 
the appendix (7). Primary ovarian mucinous tumors most frequently co-express cytokeratin 
7 (CK7) and cytokeratin 20 (CK20), whereas metastatic tumors of gastrointestinal origin are 
predominantly or exclusively CK20 positive.     
Somatic genetics in borderline ovarian tumors versus invasive carcinomas
The pattern of genetic alterations described in serous BOTs differs from that of invasive 
ovarian carcinomas. P53 mutations are most often absent in typical SBT (serous borderline 
tumors) and micropapillary SBT, but are present in up to 88% of invasive ovarian serous 
carcinoma (7;29;30). Recent studies strongly suggest that the sequence of malignant 
transformation from benign and borderline mucinous tumors to carcinoma represents 
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transitional stages of mucinous carcinogenesis. There are 3 types of RAS oncogenes (K,N 
and H), and mucinous BOTs have a higher frequency of KRAS mutation than that of 
mucinous cystadenomas, but a lower rate than that of mucinous carcinomas (7;26-28;31). 
In general, the pathogenesis of ovarian carcinomas is unknown and there is a lack of a tumor 
progression model. Shih and Kurman have described a tumor progression model based on 
clinicopathological and molecular studies (32;33). They divide epithelial ovarian tumors 
into broad categories, type I and type II tumors, corresponding to two main pathways of 
tumorigenesis. Type I tumors are composed of mucinous carcinomas, endometrioid 
carcinomas, clear cell carcinomas, malignant Brenner carcinomas and low-grade serous 
carcinomas. Type I tumors are associated with low cellular proliferation and molecular 
changes such as mutation in BRAF and KRAS oncogenes for serous carcinoma, KRAS 
mutations for mucinous tumors, ȕ-catenin and PTEN mutation for endometrioid tumors. In 
Type II tumors there are often TP53 mutations and TP53 amplification, overexpression of 
the HER2/neu gene and chromosomal instability. Shih and Kurman argue that type I 
carcinomas arise stepwise from BOTs. Type II tumors include high-grade serous 
carcinomas, malignant mixed mesodermal tumors (carcinosarcomas), and undifferentiated 
carcinomas. Shih and Kurman propose that type II carcinomas have no precursor lesion and 
develop de novo from surface epithelium of the ovary (32;33).    
Hereditary ovarian cancer
Two genes have been identified that are associated with hereditary breast/ovarian cancer 
syndrome, BRCA1 and BRCA2 (breast and ovarian cancer locus 1 and 2). Mutation in these 
genes predisposes women mainly to breast cancer, but also to ovarian cancer. For female 
carriers of BRCA1 or BRCA2 mutations, the risk of developing ovarian cancer (by 70 years 
of age) is between 15% and 66% (34;35). The risk for BRCA2 mutation carriers is on 
average less than for BRCA1 (36) mutation carriers. For women with hereditary 
nonpolyposis colorectal cancer syndrome (HNPCC), the cumulative lifetime risk for ovarian 
cancer may be as high as 10% (37;38).         
4.2.4 Clinical diagnosis of ovarian cancer
Gynecological examination, ultrasound and CT and /or MR together with serum CA 125 
concentration are used today in diagnosing ovarian cancer. Screening for ovarian cancer in 
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the general population is not currently recommended (39). The sensitivity of CA 125 in 
early-stage ovarian cancer is low, and CA 125 also lacks high enough specificity to be 
recommended alone in a screening program of the general population. Many benign 
condition are associated with elevated CA 125 serum concentrations (40;41). Several 
studies aiming at identifying new biomarkers are ongoing, and in 2012 the results of two 
large screening trials will be available (42).
4.2.5 Treatment of ovarian cancer 
Fertility-sparing surgery
In selected patients with child-bearing wish, who have stage IA and grade 1 or grade 2 
ovarian carcinomas, unilateral salpingo-oophorectomy (USO) with inspection of the 
remaining ovary and proper staging is an option, with low risk of recurrence (43). In a 
recent meta-analysis of 282 patients treated conservatively for invasive ovarian carcinomas, 
113 became pregnant, and 87 had term deliveries. Thirty-three patients (12%) developed 
ovarian carcinoma recurrence, and there were 16 disease-related deaths (4%) (44). For 
women with BOT, a meta-analysis with 1483 patients found 196 pregnancies and 111 
relapses after USO (7.5%) (44). One patient who had disease-related death was not staged 
correctly (FIGO stage unknown) (45).
Optimal surgical staging for borderline ovarian tumors
Surgical removal of BOT is the cornerstone in the treatment (13). BOT affects younger 
women than invasive carcinomas, and preserving fertility is frequently an issue. 
Conservative surgery is defined as surgical preservation of uterus and at least a part of one 
ovary to preserve fertility. Radical surgery includes total abdominal hysterectomy and 
bilateral salphingo-oophorectomy (15). Proper staging for BOTs, both conservative and 
radical approach, includes exploration of the entire abdominal cavity, cytology from ascites 
or peritoneal washing, omentectomy, multiple peritoneal biopsies and resection of possible 
implants and appendectomy (only when there is a mucinous BOT) (15). Women with 
aneuploid BOT have increased risk of dying of the disease (46) and should be radically 
operated (47). Lymphadenectomy is not recommended in women with BOTs (15;47), as the 
recurrence rate and survival rate for patients are similar with and without this procedure 
(12;48).
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Primary surgical staging for ovarian carcinomas
Surgery is the initial treatment of ovarian cancer, where removing as much as possible 
tumor volume is essential for survival (49). Surgery is also important for a correct 
histological diagnosis and for a correct surgical FIGO staging (50). FIGO staging includes 
cytology from ascites or peritoneal washing, omentectomy, complete removal of the tumor, 
lymph node sampling, hysterectomy and bilateral salphingo-oophorectomy (the latter two in 
patients not interested in or suitable for fertility-sparing surgery). Bilateral para-aortic and 
pelvic lymph node sampling is important in early-stage ovarian cancer. Among women with 
a clinically early-stage (FIGO stage I) ovarian cancer, 5-25% have lymph node metastasis 
(51-54). The incidence of positive para-aortic nodes in stage I ovarian carcinomas was 
reported to be 18% in a study by Chen and Lee (51). 
Primary cytoreduction of advanced-stage ovarian carcinomas 
Cytoreductive surgery for ovarian cancer treatment was first introduced in the 1930s by 
Meigs (55). In 1975, Griffiths published a landmark paper describing the impact of residual 
disease on survival (56). A meta-analysis on the effect of maximal cytoreductive surgery, 
removing as much tumor volume as possible, showed a statistically significant positive 
correlation between percent maximal cytoreduction and log median survival time (49). A 
consensus statement on management of ovarian cancer concluded in 2004 that maximal 
surgical effort at cytoreduction with the goal of no residual disease was the aim and when 
cytoreductive surgery is not possible initially, it should be considered in patients who do not 
have progressive disease after 3-5 cycles of chemotherapy (50).
Chemotherapy
The current standard treatment for advanced-stage ovarian carcinomas is a combination of 
paclitaxel and carboplatin given adjuvant to surgery (57-59). Adjuvant chemotherapy (AC) 
for early-stage ovarian cancer is controversial (60). Patients who are staged incompletely at 
primary operation should be completely surgically staged (including lymph node sampling) 
before a final decision can be made regarding the need for AC in this group. Clinical FIGO 
stage and sub-stage, DNA ploidy and preoperative CA 125 should also be taken into 
consideration when making this decision (60). 
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Targeted therapy in ovarian cancer
Targeted therapy has been shown to prolong patient life in some carcinomas, most 
convincingly in breast cancer. Breast cancer patients whose tumors overexpress HER2/neu 
are now treated with a monoclonal antibody (trastuzumab) targeting this receptor (61). In 
ovarian cancer, targeted therapy is currently evaluated through angiogenesis inhibition. 
Bevacizumab is a monoclonal antibody blocking the VEGF-A receptor, evaluated in breast 
cancer therapy. Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab 
prolongs progression-free survival, but not overall survival, as compared with paclitaxel 
alone (62). Today, there are two ongoing phase III trials with targeted therapy for ovarian 
cancer initiated by the Gynecologic Oncology Group (GOG 218) and International 
Collaborative Ovarian Neoplasm (ICON 7) (63). Both trials include standard carboplatin 
and paclitaxel treatment, together with bevacizumab, as front line therapy in ovarian cancer, 
in patients with newly diagnosed disease (64). GOG 218 is a three-arm, placebo-controlled 
trial, for patients with stage III-IV disease. ICON7 include all patients with ovarian cancer 
(also early-stage, high-risk) and is a two-arm trial without placebo, with 6 cycles of 
bevacizumab versus extended 12 cycles, the end point being progression free survival (63).
4.3 Biomarkers of ovarian tumors 
A biomarker is defined as a measure indicator of a specific biological state, particularly one 
relevant to the risk of the presence or the stage of a disease (65). Biomarkers can be used 
clinically to screen for, diagnose or monitor the activity of diseases and as a guide for 
molecular targeted therapy or in assessment of therapeutic response (66).
The ovarian cancer biomarker CA 125 was first identified in 1981 (67), and is a large 
membrane-bound glycoprotein whose biological function remains unknown (68). CA 125 is 
the epithelial ovarian cancer biomarker of practical clinical use today, used to monitor 
response to chemotherapy, to detect disease recurrence and to distinguish malignant from 
benign pelvic masses (69). Jacobs et al. developed a risk of malignancy index incorporating 
CA 125, ultrasound and menopausal status that will estimate the probability of malignant 
potential for pelvic mass with a sensitivity of 85% and a specificity of 97% (70). 
Unfortunately, CA 125 is frequently elevated in noncancerous conditions, such as 
pregnancy, endometriosis, uterine fibroids, liver diseases and benign ovarian cysts, and in 
other malignancy, such as colon, uterine, fallopian, gastric and pancreatic cancers (71). CA 
19
125 has low sensitivity for early-stage ovarian carcinomas (41), and CA 125 is not 
recommended as a screening marker in women who are not at high risk or do have specific 
symptoms of the disease (72).  
Early-stage cancer lesions are small in tissue volume, thus limiting the biomarker 
production rate into a level well below the threshold of detection in circulation by most 
diagnostic platforms today. Low biomarker concentrations, especially for early-stage, 
reduce test sensitivity (71). Epithelial ovarian cancer is a very heterogeneous group of 
tumors as shown earlier in the introduction, with different genetic alterations and potential 
growth pathways. 
Biomarkers can be measured in the circulation as well as at tissue level. Molecular markers 
can be detected on chromosomal level such as mutation (TP53), deletion (TP53 and TP16) 
or amplification (AKT2 and HER2/NEU)) of tumor suppressor genes or oncogenes. There 
are several classes of molecules involved in growth stimulatory pathways, including growth 
factors, transcription factors, and cell cycle proteins. These biomarkers can be measured on 
gene level (e.g. by microarray or fluorescent in situ hybridization), on mRNA level (e.g. by 
in situ hybridization, northern blot or RT-PCR) or on protein level (e.g. by 
immunohistochemistry or proteomics). There have been numerous studies of the prognostic 
impact of molecular markers for ovarian cancer. However, these studies have not yet 
resulted in the implementation of new molecular markers for diagnosis and follow-up. 
4.4 Biomarkers explored in this thesis 
4.4.1 AP-2Ȗ and c-kit 
The control of the gene expression is complex. Gene expression with transcription of the 
gene into mRNA is initiated by binding of transcription factors to the promoter. Several 
transcription factors are tissue specific. Activator protein-2 (AP-2) transcription factors are 
involved in the regulation of cell proliferation, differentiation, apoptosis and carcinogenesis 
(73-75). AP-2 transcription factors represent a family of five closely related proteins, termed 
Į-İ, which are encoded by distinct genes (74). AP-2Į, AP-2ȕ and AP-2Ȗ are the most well 
known members. These transcription factors are involved in cancer proliferation by directly 
activating the promoter of several central growth- and differentiation-related genes such as 
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p21WAF1 (76), ER-Į (77) and HER2/neu (73). In studies of melanoma cell lines, loss of AP-
2Į expression has been associated with several invasion- and metastasis-promoting events 
such as overexpression of the cell adhesion molecule MCAM/MUC18 and protease-
activated receptor (PAR)-1, as well as downregulation of the tyrosine kinase receptor c-kit 
(78-80). An earlier study showed c-kit to be infrequently expressed in ovarian carcinomas 
(81).
The exact role of AP-2 transcription factors in human cancer development is not entirely 
established. However, there is growing evidence that the net effect of whether the cell 
proliferates, undergoes apoptosis or differentiates may partly be dependent on the balance 
between different AP-2 proteins (82;83). The role of AP-2Ȗ may differ from that suggested 
for AP-2Į (83). Different tumors have different expression of AP-2Į and AP-2Ȗ. AP-2Ȗ also 
plays an essential role in early embryogenesis. Transgenic embryos lacking AP-2Ȗ die soon 
after implantation (84;85). In breast cancer, the chromosomal locus of AP-2Ȗ gene is often
amplified, and this gene amplification is associated with poor prognosis (86). In HER2/neu 
overexpressing transgenic mice, AP-2Ȗ expression is initially delayed, but when tumor 
growth is accelerated, AP-2Ȗ expression increases (82). The only published study of AP-2 
expression in ovarian carcinoma, to the best of our knowledge, analyzed AP-2Į. In this 
study, nuclear AP-2Į expression and absence of cytoplasmatic staining predicted worse 
prognosis (87).
4.4.2 Nerve growth factor receptors and intracellular signaling  
Neurotrophins are a family of growth factors, in which nerve growth factor (NGF) is the 
prototype molecule. Their biological functions are mediated through binding to two classes 
of cell surface receptors, to the high-affinity tyrosine kinase receptor tropomyosin receptor 
kinase A (TrkA) and the low affinity neurotrophin receptor p75 a member of the tumor 
necrosis family (88). As for many other growth factors, dysregulation of neurotrophin signal 
transduction is found in a number of tumors where they can contribute to malignant 
transformation (89). TrkA was originally discovered as a colon carcinoma oncogene (90). 
Rearrangement or mutation of the TrkA gene, resulting in constitutive activation of the 
receptor, has been observed in colon carcinomas, thyroid papillary carcinomas, as well as in 
acute myeloid leukemia (91). Overexpression of TrkA in different tumors, including 
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prostate, pancreas, thyroid, lung, breast and ovarian carcinoma, and in malignant melanoma, 
is associated with poor prognosis (92-98).
The evidence regarding the biological role of p75 in human cancer is more limited. Frequent 
expression was seen in some neural and soft tissue tumors, while most carcinomas were 
negative (99). Furthermore, p75 expression has been found to be reduced in carcinomas 
compared to non-neoplastic tissue (100), although the latter finding was not confirmed in an 
additional study (101). 
NGF ligand binding to TrkA receptors activates TrkA autophosphorylation at several sites 
(102;103). Recent studies of TrkA signaling in different cancers suggest that TrkA 
engagements leads to the activation of a variety of intracellular pathways, such as the 
mitogen-activated protein kinase (MAPK) pathway and the phosphoinositol-3-kinas 
(PI3K)/AKT pathway (103-105).The mitogen-activated protein kinase (MAPK) intracellular 
signaling is a four-kinase component cassette, in which each kinase activates the following 
kinase substrate through a complex network, enabling the cell to maintain diversity and 
specificity while responding to various extracellular stimuli (106). The final level consists of 
extra-cellular regulated kinase (ERK), c-jun amino-terminal kinase (JNK), and the high-
osmolarity glycerol response kinase (p38). JNK and p38 are known to be activated by stress-
related stimuli, and are thought to largely mediate apoptotic signals. ERK members are 
largely activated by growth factor signals, as those mediated by receptor tyrosine kinase, the 
net result being growth, differentiation, and proliferation (107). Givant-Horwitz et al. reported 
three activated forms of MAPK to be predictors of improved clinical outcome in effusions 
from serous ovarian carcinoma patients (106). In primary ovarian carcinomas, p-ERK is more 
frequently expressed in low-grade compared with high-grade tumors and correlates with 
better survival (108). 
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Figure 3: Factors explored in the thesis by immunohistochemistry. 
Growth factors bind to the two cell surface membrane receptors explored in this 
thesis, TrkA or p75. TrkA receptors carry thyrosine kinase domains on their 
cytoplasmatic side. Growth factor binding to the receptor leads to phosphorylation of 
parts of intracellular pathways, such as MAPK and/or p13/AKT pathways (103-105). 
Activation of MAPK intracellular pathways, mediates cell proliferation, apoptosis 
and differentiation (107).
Ap-2Ȗ transcription factor is involved in tumor proliferation by directly activating 
the promoter of several central proliferation related genes (73;76;77).
4.4.3 Calprotectin
Already in 1863, Rudolf Virchow noted the presence of leukocytes in neoplastic tissues and 
made a connection between inflammation and cancer (109). Since then, many experimental 
studies and clinical observations have linked cancer and inflammation (reviewed in 
(109;110)). The calprotectin protein is an inflammation marker, and has been associated 
with some forms of cancer.  
Human leukocyte protein L1, later named calprotectin, was first described in 1980 by 
Fagerhol et al. (111). Calprotectin is a protein mainly found in granulocytes and monocytes, 
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it is a major calcium- and zinc-binding protein. Calprotectin is released by activated 
neutrophils (111;112). This 36.5 kD heterodimer protein molecule contains two 13.3 kD 
heavy (L1 heavy or MRP14) and one 8.2 kD light (L1 light or MRP 8) polypeptide chains 
(113). Each chain can bind two calcium ions. Other names for calprotectin include 
MRP8/MRP14 (114;115), 27E10 antigen (115), S100A8/S100A9 (116;117) complex and 
calgranulin (118;119).
Calprotectin plays a role in various physiological functions such as inflammatory processes, 
inhibition of cell proliferation, and in the neutrophil defense against bacterial infections 
(120). Apoptosis (programmed cell death) is linked with many pathological conditions such 
as inflammation and tumor growth. Calprotectin has cytokine like effects (121;122) 
including a proinflammatory cytokine function (117), as well as a chemotactic factor 
activity (123).   
Matrix metalloproteinases (MMPs), family of zinc-dependent proteases, are able to break 
down extracellular matrix (ECM). MMPs are important in many normal biological 
processes, including embryonic development, angiogenesis, and wound healing, as well as 
being important in pathological processes such as inflammation and cancer (124). The 
metalloproteinases are totally dependent on zinc for their enzymatic activities (124) and 
Isaksen and Fagerhol demonstrated that calprotectin inhibits MMPs by competing with 
these enzymes for zinc (125). Among the MMPs that can be inhibited is collagenase B 
(MMP-9), known to be important during angiogenesis and invasive tumor growth. 
Calprotectin is a member of the S100 protein family. The S100 genes are located in a gene 
cluster on chromosome 1q21 (126;127). This region has been identified as a target region 
for transcriptional activation in common human epithelial malignancies (128;129). S1008A 
and S1009A genes are overexpressed in gastric cancer, as demonstrated by RT -PCR on 
frozen tissue (130). Immunohistochemical investigations have shown that S100A9 protein is 
overexpressed in hepatocellular carcinomas, pulmonary adenocarcinomas, and invasive 
ductal carcinomas of the breast (131-133). In these tumors, elevated expression of S100A9 
correlated with poor differentiation. Calprotectin has been shown to be elevated in the 
circulation (serum) and in fecal specimens from patient with colorectal carcinomas (134), 
and in serum as well as in the primary tumor in prostate cancer (116).  
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To our knowledge, the only published study of calprotectin expression in ovarian cancer 
was performed using gel electrophoresis. In this study, Ott et al. demonstrated elevated 
calprotectin concentration in ovarian cystic fluid as well as serum in women with ovarian 
cancer (n=11) compared to benign ovarian cysts (119).
The mechanisms behind the elevated plasma calprotectin levels and the exact roles of 
calprotectin in cancer are at present unclear.   
4.4.4 Endoglin
Endoglin (Eng), also named CD105, is a cell-surface co-receptor for TGF (transforming 
growth factor)-ȕ1 and -3, and is highly expressed on endothelial cells. The TGF-ȕ
superfamily consists of growth factors that govern a wide range of cellular functions, such 
as cell growth, differentiation, and migration (135). The TGF-ȕ actions are mediated 
through intracellular signaling mediators, known as Smads (135), which alter transcriptional 
responses (136). Endoglin modulates the actions of for TGF-ȕ family of growth factors, 
without interfering with ligand binding (137), and has been described as proliferation-
associated antigen of leukemia and endothelial cells (138). TGF-ȕ inhibits endothelial cell 
proliferation, migration and formation of microvessels. Cell-bound endoglin counteracts 
these actions, thereby promoting angiogenesis. Cell-bound endoglin antagonizes the 
inhibitory signaling of TGF-ȕ1 on human vascular endothelial cells, and normal levels of 
endoglin are required for formation of new blood vessels (139). Endoglin is overexpressed 
on highly proliferating endothelial cells in culture (138). In immunohistochemistry studies, 
CD105 is strongly expressed in blood vessels of tumor tissues in breast, colon and prostate 
cancer, brain and cervical cancer (140).  
Microvessel density (MVD) is an immunohistochemistry based method, and determines 
neovascularization in tumor tissue with use of immunohistochemical markers for 
endothelial cells. MVD is assessed in the tumor areas with the greatest density of stained 
capillaries, and the number of vessels per high-power microscopic field is counted (141). 
Endoglin (CD105) positive immunohistochemistry has been used to assess intratumoral 
MVD, and several studies have shown that endoglin reflects neo-angiogenesis in tumor 
vasculature better than panendothelial markers, such as von Willebrand factor (vWF, also 
named factor VIII-related antigen), CD34 and CD31 (140). In ovarian cancer, endoglin 
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(CD105) was found to be an independent predictor of poor survival, and endoglin was a 
better predictor for MVD than CD31 (141).
Circulating endoglin (sEng, soluble endoglin) represents a soluble form of the cell-bound 
endoglin protein. sEng is an N-terminal cleavage product of full-length Eng but lacks the 
cytoplasmatic tail and transmembrane domain (142). Previous studies have shown that sEng 
correlates with metastasis and poor survival in colorectal, breast and lung cancer (143). 
Plasma levels of sEng correlate with metastasis in women with breast cancer, and the 
protein might be an angiogenetic marker for identifying breast cancer patients who are at 
high risk for developing metastasis (144). To the best of our knowledge, there is no 
published study exploring soluble endoglin in epithelial ovarian cancer.
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5. AIMS OF THE THESIS 
More knowledge regarding signaling pathways in the malignant transformation is important 
to improve both ovarian cancer diagnosis and treatment. The overall aim of the present 
thesis was to explore some molecular markers possibly involved in ovarian carcinogenesis, 
and to investigate whether BOTs and invasive carcinomas differentially express these 
biomarkers. The study also aimed at evaluating the current surgical treatment of BOTs.  
Specifically, the aims were to: 
1. Evaluate retrospectively surgical techniques (laparoscopy versus laparotomy) in women 
operated for BOTs, assessing preoperative, perioperative and postoperative findings. We 
also wanted to reevaluate histologically the BOT diagnoses, including the diagnoses of all 
benign or malignant ovarian tumors operated at Department of Obstetrics and Gynaecology, 
Ullevål University Hospital. 
2. Analyze the expression of the AP-2J transcription factor in BOTs, early-stage ovarian 
carcinoma and advanced-stage ovarian carcinoma, and to evaluate its prognostic role in 
advanced-stage tumors.  
3. Study the expression of the nerve growth factor receptors TrkA and p75 in ovarian BOTs, 
early-stage ovarian carcinoma and advanced-stage ovarian carcinoma. 
4. Assess a possible association between expression of the nerve growth factor receptors 
TrkA and p75 and mitogen-activated protein kinase (MAPK) in ovarian BOTs and FIGO 
stage I carcinomas.  
5. Explore whether calprotectin, an inflammation marker, can be used as a plasma or 
effusion biomarker of ovarian cancer.  
6. Investigate whether endoglin (CD 105), a protein highly expressed in tumor 
neoangiogenesis and elevated in the circulation in some cancer forms, can be used as a 
biomarker for ovarian cancer, either in plasma or in effusions.  
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6. MATERIALS AND METHODS 
6.1 Patient selection
Biological material from 3 different biobanks (A-C) was used in Papers II-IV: 
Biobank A is the GSI (Gynecological tumors- svulster in Norwegian- and Invasion 
potential) study biobank at Ullevål University Hospital, and was used in Papers III and IV.
This biobank was established in 2003 by the Ullevål research group (Associate Professor 
Annetine Staff, Professor Mathias Onsrud, and MD Elin Ødegaard) and is an ongoing
biobank collection, including surgical material from women operated for ovarian tumors
(benign tumors, BOTs and invasive ovarian carcinomas) at the Department of Obstetrics 
and Gynaecology, Ullevål University Hospital. The collection of biological material and 
pre-, peri-and postoperative clinical information was collected for use in this thesis, from
January 2003 until 2006. Serum and EDTA-plasma blood samples were obtained 
preoperatively from all the patients included in Papers IV and V. All tumors from women
included in Papers IV and V from the GSI study were reevaluated histologically by 
Consultant Vibeke Engh, a senior pathologist at Ullevål University Hospital. Only the blood
samples, not the tumor tissue, of the patients recruited from the GSI biobank were used for 
analyses in Papers IV and V.
Biobank B is an effusion and tumor biobank at the Department of Pathology, Norwegian 
Radium Hospital, Rikshospitalet Medical Center (in this thesis abbreviated to the RH
biobank). The biological specimens were collected from 1991 to 2002, under the 
supervision of Associate Professor Ben Davidson.
Effusions
Ascites and pleural effusions from women with  FIGO stage II-IV carcinomas were used in 
Paper II (168 women), and in Paper V (164 women). We did not have available effusions 
from women with benign ovarian tumors, as these rarely produce ascites or pleural effusions
(except for Meig’s tumors).
Tumor tissue
In Paper II, the tumor material consisted of sections from patients included in the RH 
biobank; 14 benign ovaries from patients operated for non-metastatic endometrial
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carcinomas, 31 BOT, 22 primary stage I ovarian carcinomas, 42 primary advanced-stage 
(FIGO III-IV) carcinomas (40 serous, 1 undifferentiated and 1 mixed epithelial tumor) and 
62 solid metastases. Tissue microarray (TMA) sections for c-kit immunostaining were from 
35 patients with advanced-stage carcinomas (primary tumors, solid metastases and 
effusions). These 35 patients were part of the cohort studied for AP-2J protein expression in 
Paper II. In Paper III, sections from 75 BOT, 57 FIGO stage I carcinomas and 56 advanced-
stage carcinomas (24 primary and 32 metastatic lesions) from the RH biobank were used. 
All tumors from the RH biobank were histologically reevaluated by a senior pathologist 
(Ben Davidson). Borderline tumors were additionally evaluated by another senior 
pathologist (Vera Abeler). 
Biobank C is a tumor biobank from the Department of Pathology at Sheba Medical Center 
in Israel. The tumor samples were from 44 paraffin blocks of borderline ovarian tumors and 
were used in Papers II and III. All tumor slides were diagnostically reevaluated by the same 
two senior pathologists as for Biobank B (Vera Abeler and Ben Davidson).
Surgical borderline ovarian tumor (BOT) patient population 
In Paper I, we performed a retrospective comparison of short time outcome after surgery by 
laparoscopy or laparotomy in women with stage I ovarian borderline tumors during a five-
year period (January 2000 to December 2004). In this period, 603 women with ovarian 
tumors were operated at the Department of Obstetrics and Gynaecology at Ullevål 
University Hospital, and of these, the 112 identified patients with BOT were included in the 
retrospective study. All tumors were reevaluated histologically by the same senior 
pathologist at Ullevål University Hospital as in Papers IV and V (Vibeke Engh). The 
medical records of all 112 patients with BOT stage I disease were studied retrospectively, 
supplemented by information from the patient’s gynecologist or from the patients 
themselves if the last consultation was outside the hospital.  
Ethical approval
The GSI biobank study (Papers IV and V) and the BOT operative study (Paper I) were both 
approved by the Regional Committee of Medical and Health Research Ethics in Eastern 
Norway and informed written consent was obtained from each patient. The effusion and 
tumor study (Papers II, III and V) from the RH biobank was approved by the Regional 
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Committee of Medical and Health Research Ethics in Southern Norway. Local ethical 
consent was obtained for the Israeli study in Israel. Norwegian regulatory rules and laws, 
including Data Inspectorate regulations and Biobank law, were followed strictly, including 
the handling of the Israeli tumor biobank tissue (evaluated and transported anonymously). 
6.2 Laboratory methods 
Preparation of effusions 
Fresh (non-fixed) peritoneal and pleural effusion from ovarian cancer patients were obtained 
from Biobank B (RH biobank). All effusions were morphologically evaluated by an 
experienced cytopathologist (Associate Prof. Ben Davidson). All specimens containing 
degenerated cells were excluded from the study. Specimens that contained a large amount of 
viable cells (malignant-appearing epithelial cells, mesothelial cells, or both) were processed 
immediately after tapping. Part of the material was fixed in formalin and used for the 
preparation of a cell block (Paper II). The other part of the material was centrifuged at 2000 
rpm for 10 minutes, and separated into cell pellets (used in Paper II) and supernatants (used 
in Paper V). Both were frozen at –70oC.
Immunohistochemistry (IHC)
Four to six micron thick sections from ovarian tumors were formalin–fixed, paraffin–
embedded and mounted on coated slides for IHC (Papers II and III). The slides were 
immunostained using the DAKO EnVision TM + peroxydase system (DakoCytomation, 
Glostrup, Denmark). Deparaffinized sections were microwaved in buffer, as described in 
Papers II and III, in order to unmask the epitopes, and then treated with hydrogen peroxide 
(H2O2) for 5 minutes for blocking endogenous peroxidase. Incubation was done with 
mono- or polyclonal rabbit antibodies (see Papers II and III). The sections were then 
incubated with the respective antibodies followed by incubation with the secondary 
antibody, the peroxidase-labeled polymer conjugated anti-rabbit or anti-mouse, for 30 
minutes. Tissues were stained for 5 minutes in freshly prepared diaminobenzidine 
terahydrochloride (DAB), and then counterstained with haematoxylin, dehydrated and 
mounted on slides. All series included positive controls, consisting of sections from invasive 
ovarian carcinoma tissue that was shown to express the protein in a pilot study. The 
exception to this was the c-kit positive control, which was an appendix specimen. All series 
included negative controls, performed on sections from the same tumor tissue as the positive 
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controls; the negative controls underwent similar staining procedure, except for the primary 
antibody application. Most of the IHC in Papers II and III was performed by the PhD 
student Elin Ødegaard, the remaining slides were stained by two technicians, Inger Liv 
Nordli and May Nguyen. 
Western blots 
Cells from Biobank B (RH biobank) effusions and ovarian carcinomas cell lines (SKOV-3 
and OVCAR-3) were studied for AP-2J expression (see Paper II). This Western 
immunoblotting was performed by Martina Skrede. Totally, 61 (45 peritoneal, 16 pleural) 
malignant effusions from advanced-stage ovarian carcinoma patients and the ovarian 
carcinoma cell lines SKOV-3 and OVCAR-3 were studied for AP-2Ȗ expression. Frozen 
samples were thawed, washed twice in cold PBS, and lysed in NP-40 ice-cold lysis buffer 
(1% NP-40, 10% glycerol, 20mM Tris-HCl [pH 7.5], 137mM NaCl, 100mM NaF, 1mM 
sodium vanadate, 1mM phenylmethyl sulphonyl fluoride, and 0.02mg/ml each of leupeptin, 
pepstatin, and aprotinin, and 10Pl/ml phosphatase inhibitor cocktail I). All inhibitors were 
from Sigma-Aldrich, St. Louis, MO. Lysates were then sonicated and centrifuged. Protein 
was quantified by Bradford analysis and 25 micrograms of total cellular protein were loaded 
into each lane, separated by electrophoresis through SDS-12% polyacrylamide gels (SDS-
PAGE), blotted onto immobilon-P-membranes (Millipore Corporation, Bedford, MA) and 
blocked in 5% non-fat dry milk in TBS-T. The filters were subsequently hybridized with the 
antibody against AP-2Ȗ used for IHC, using a concentration of 1Pg/ml. A mouse 
monoclonal antibody against D-tubulin (clone 57) (Oncogene, San Diego, CA) was used as 
loading control at a concentration of 1:5000. After washing in TBS-T, bound antibody was 
visualized using peroxidase-conjugated anti-mouse IgG and the ECL detection system 
(Amersham Pharmacia, Buckinghamshire, UK). Negative controls consisted of antibody in 
the absence of lysate.  
ELISA
Enzyme-linked immunosorbent assay method was used for protein measurement of 
calprotectin and endoglin in plasma and ascites, and was mainly performed by technicians.  
ELISA for calprotectin was performed at the Department of Immunology and Transfusion 
Medicine, Ullevål University Hospital (Paper IV) on plasma samples from Biobank A and 
on effusion samples from Biobank B (Paper V). A plasma volume of 100 uL was diluted 
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1/50 in an assay buffer containing 10g/L bovine serum albumin, 50 mmol/L tris, 150 
mmol/L sodium chloride, 0.5 mmol/L magnesium chloride, 2.5 mmol/L potassium chloride, 
0.25 mmol/L thimerosal, and 0.05% Tween-20, pH 8.0. The standards and diluted samples 
were added to microtiter wells and shaken for 30 minutes at room temperature. After 
washing, alkaline phosphatase-conjugate was added, and the plate was shaken again. After a 
final wash, substrate was added and the optical density was read. Coefficients of variation 
were 5% within and 13% between assays.
Enzyme-linked immunosorbent assay for human endoglin (Paper V) was performed in 
duplicates on plasma samples from Biobank A and on effusion samples from Biobank B, 
according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN).  
Routine blood analyses 
High-sensitivity C-reactive protein (CRP) was measured in serum (Paper IV) with a Hitachi 
917 instrument by particle-enhanced immunoturbidimetric assay (Tina-Quant CRP, Roche 
Diagnostics Corporation, Indianapolis, IN), measuring the range of 0.1-300 mg/L. 
White cell count was assessed using a Sysmex SE 9500 (TOA Medical Electronics, Kobe, 
Japan).
Serum CA 125 concentration (Papers I and IV) was measured with an ARCHITECT 
system using a two-step immunoassay technology (Abbot Laboratories, Abbott city, IL). 
6.3 Statistics
The results in Paper I to V were usually not normally distributed. Median and range or 
median and a 95% confidence interval of the median were reported. In Papers I, II, IV and 
V we used Mann-Whitney test when analyzing numerical or continuous variables. In Paper 
V we also performed the Kruskall-Wallis test (for > 2 categories, e.g. histological grade). In 
Papers I-V, categorical variables were analyzed by Chi-square test or Fisher’s exact test 
(when the expected values were less than five in a 2x2 table). Comparative analysis of the 
AP-2Ȗ protein expression (Paper II) in primary and metastatic advanced-stage carcinomas 
was performed using the Wilcoxon signed ranks test. Univariate survival analyses for 
patients with advanced-stage tumors were analyzed by the Kaplan-Meier method (Paper II 
and Paper V). In Paper IV, Receiver Operating Characteristic (ROC) curves were 
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constructed for calprotectin and CA 125 evaluations. In Papers IV and V, we also performed 
Spearman’s correlation to calculate correlation coefficients. The statistical analyses were 
performed with the Statistical Package for the Social Sciences (SPSS, version 13-14, 
Chicago, IL). A significance level of 5% was used.
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7. SUMMARY OF RESULTS 
Table 1 gives an overview of the results of this thesis regarding tissue-investigated, plasma- 
and effusion-investigated potential protein biomarkers for women with ovarian tumors 
(Papers II-V). 
Paper I: Surgery of borderline tumors of the ovary: retrospective comparison of short-
term outcome after laparoscopy or laparotomy 
All ovarian tumors operated during a 5-year period at our Department of Obstetrics and 
Gynaecology (January 2000 through December 2004) were reevaluated histologically by 
one senior pathologist. Of the 603 tumors, only 3 (0.5%) were reclassified during the 
histological revision, with 1 benign cyst being upgraded to BOT, 1 BOT being downgraded 
to benign cyst, and 1 invasive carcinoma being downgraded to BOT. In the histological 
reevaluation of the 603 patients, 19% were classified as BOT (n=107), 33% as carcinomas 
and 48% as benign ovarian tumors.  
In Paper I we also retrospectively evaluated the short-term outcome for the 107 women 
operated in this 5-year period for BOT, FIGO stage I, comparing two different surgical 
approaches (laparoscopy and laparotomy). Women who initially underwent laparoscopy, but 
during the operation had a conversion to laparotomy, were analyzed in the laparotomy 
group. Women operated by laparotomy in a first operation (n=69) were more often 
postmenopausal and had a higher CA 125 preoperatively than women operated by 
laparoscopy (n=38). The median tumor size was larger in the laparotomy group compared to 
the laparoscopy group (16.4 cm versus 8.6 cm, p<0.001). Tumor rupture during operation 
was more frequent in the laparoscopy group, 29% versus 16%, but this difference was not 
statistically significant (p=0.2). In a sub-analysis of tumors exceeding 10 cm in diameter, we 
found significantly more frequent rupture with laparoscopy than laparotomy (p=0.014). 
Postoperative complications were analyzed combining primary and a potential second 
operation in the laparotomy group (n=73), and were more frequent than in the laparoscopy 
group (18% versus 3%, p=0.03), wound hematoma representing the most frequent 
complication. Median hospital stay was also longer for patients operated by laparotomy (5 
versus 1.7 days, p=0.001). The laparoscopic surgeries were however less extensive as 
compared to laparotomy surgeries, and did not include hysterectomy.  
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Paper II: The AP-2Ȗ transcription factor is upregulated in advanced-stage ovarian 
carcinoma
AP-2J transcription factor seems to be involved in the regulation of many factors that are 
altered in cancer, such as proliferation, cell cycle regulation, inhibition of apoptosis and 
invasion, but their exact role in tumor genesis is not established. In Paper II, sections from 
14 normal ovaries, 75 BOT, 22 FIGO stage I ovarian carcinomas and 306 advanced-stage 
(FIGO II-IV) ovarian carcinomas (42 primary tumors, 62 metastases and 202 effusions) 
were analyzed for expression of the transcription factor AP-2Ȗ by immunohistochemistry. 
Also, 63 effusions and 2 cell lines (SKOV-3 and OVCAR-3) were studied using 
immunoblotting. AP-2Ȗ was detected predominantly in the nucleus of BOT (37%), FIGO 
stage I carcinomas (59%), and primary tumors from advanced-stage carcinomas (93%), and 
in cancer cells of effusions from women with advanced-stage carcinomas (79%). The 
surface epithelium of benign ovaries did not express the AP-2Ȗ protein by 
immunohistochemistry. AP-2Ȗ nuclear expression was upregulated in advanced-stage 
ovarian carcinomas (p<0.001) compared to stage I carcinomas and BOT. AP-2Ȗ expression 
did not correlate with protein expression of the tyrosine kinase receptor c-kit, although these 
proteins have previously been shown to be co-expressed in melanoma. Analysis from 
corresponding primary tumors, metastasis and effusions from advanced-stage cases showed 
no difference in AP-2Ȗ nuclear expression (p>0.05). AP-2Ȗ expression in primary tumors of 
advanced-stage, solid metastases or effusions did not correlate with progression-free or 
overall survival time period for the included women.  
Paper III: The activated nerve growth factor receptor p-TrkA is selectively expressed 
in advanced-stage ovarian carcinomas 
We wanted to analyze the association between NGF receptor expression and the malignant 
potential in ovarian tumors, as NGF induces cell proliferation via activation of TrkA and 
MAPK in breast cancer cell lines. We compared the expression of the NGF receptors p-
TrkA (a high-affinity receptor) and p75 (a low-affinity receptor) in borderline tumors and 
invasive ovarian carcinomas. Sections from 119 BOT, 57 FIGO stage I ovarian carcinomas, 
and 56 advanced-stage ovarian carcinomas were immunostained for p-TrkA, p75 and the 
activated forms of MAPK (p-ERK, p-P38 and p-JNK). We found an up-regulation of p-
TrkA in advanced-stage carcinomas as compared to stage I carcinomas (p<0.001). There 
was no significant difference in p-TrkA protein expression between BOT and stage I 
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ovarian carcinomas. p75 results showed low membrane expression in all 3 groups, and no 
difference between the BOT, early- and advanced-stage ovarian carcinomas (p>0.05).  
MAPK nuclear protein expression was very high in both the BOT and stage I carcinoma 
group, but there were no statistical differences between these tumor groups with respect to 
p-ERK or p-P38 expression. P-JNK was more frequently expressed in stage I ovarian 
carcinoma compared with BOT (p<0.001). We found no association between NGF receptor 
expression and MAPK activation in BOT and stage I carcinomas. 
Paper IV: Circulating calprotectin in ovarian carcinomas and borderline tumors of the 
ovary
We included 199 women from our biobank research study (GSI) at Ullevål University 
Hospital. Calprotectin, a marker of inflammation, may be involved in tumor development, 
but the exact biological role remains to be defined. Calprotectin was analyzed using ELISA 
in EDTA-plasma collected prior to surgery from women with ovarian carcinomas (n=89), 
borderline ovarian tumors (BOT, n=39) and benign ovarian tumors (n=71). Median plasma 
concentration of calprotectin was significantly elevated in women operated for invasive 
cancer (2512 μg/L) compared to borderline (985 μg/L) and benign tumor groups (951 μg/L) 
(both p<0.001). Median plasma calprotectin concentration did not differ between the BOT 
and benign control groups. Serum CA 125 was analyzed in the same study population. A 
positive correlation was found between CA 125 and calprotectin concentrations in ovarian 
carcinoma (Spearman’s correlation: 0.5, p<0.05). In order to explore whether calprotectin 
could represent an improved marker as compared to CA 125 in identifying ovarian cancer, 
we used a receiver operating characteristic (ROC) curve, plotting the sensitivity versus 1-
specificity for each possible cut-off. The ROC curve demonstrated a larger area under the 
curve for CA 125 (0.85) as compared to calprotectin (0.70), suggesting that plasma 
calprotectin is inferior to CA 125 when used as an ovarian cancer biomarker.   
Paper V: Endoglin and calprotectin as potential biomarkers in ovarian carcinoma and 
borderline tumors of the ovary
In this study we used the same GSI biobank plasma material as in Paper IV, including 
women with benign ovarian tumors (n=71), BOT (n=39) and ovarian carcinomas (n=89). In 
addition, we included effusions from 164 women with advanced-stage ovarian carcinoma. 
Plasma samples and effusion supernatants were analyzed for endoglin by ELISA. 
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Calprotectin was analyzed in the effusion specimens by the same immunoassay as in Paper 
IV. Unexpectedly, a slightly higher median plasma concentration of endoglin was found in 
the BOT group as compared to both control and invasive cancer group (4.9 versus 4.5 and 
4.3 ng/mL, p=0.02 and p=0.04). Median plasma endoglin concentration did not differ 
significantly between the control and invasive groups (4.5 vs 4.3 ng/mL, p=0.08). For the 
total group, there was no correlation between serum CA 125 and plasma endoglin 
concentrations. In effusions, calprotectin had a medium concentration of 2509 ȝg/L and 
median calprotectin concentration was significantly higher in effusion obtained prior to 
chemotherapy administration compared to post-chemotherapy specimens (p=0.007). 
Endoglin concentration in effusions supernatants had a medium value of 3.6 ng/mL, which 
was of corresponding magnitude to the median plasma concentration, although measured in 
different patient populations. Endoglin and calprotectin effusion concentrations did not 
correlate with overall or progression-free survival, or showed any association with 
histological grade, FIGO stage or extent of residual disease (all p>0.05). 
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Biomarker Laboratory
method
(and biological 
material)
BOT Ovarian
carcinoma
(FIGO I)
Ovarian
carcinoma
(FIGO III-IV)
Effusions
(FIGO III-IV)
Paper
 Ap-2Ȗ
(transcription
factor) b) c)
IHC
(paraffin
sections)
Western
(malignant 
effusions)
ļ ļ Ĺ Ĺ
frequent
expression
No correlation 
with survival
II
TrkA (nerve
growth factor)
b) c)
IHC
(paraffin
sections) ļ ļ Ĺ Ĺ
III
MAPKs
(intracellular
signaling
pathways) b) c)
IHC
(paraffin
sections)
Ĺ Ĺ
III
Calprotectin
(inflammation 
marker) a) b)
ELISA
(plasma) 
(effusions)
ļ ļ Ĺ
No correlation 
with survival 
IV
V
Endoglin
(angiogenic
factor) a) b)
ELISA
(plasma) 
(effusions)
(Ĺ) ļ ļ
No correlation 
with survival
IV
V
Table 1: Summary of results in Papers II-V
As compared to controls: ļ:  no significant difference, Ĺ: higher in, Ļ:  lower in
a) GSI biobank (biobank A)
b) RH biobank (biobank B)
c) Israeli biobank (biobank C))
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8. GENERAL DISCUSSION 
8.1 Patient selection
Population used in Paper I
In Paper I we used a retrospective design to compare the two different surgical methods in 
women operated for stage I BOT, laparoscopy and laparotomy, in a five-year period from 
January 2000 to December 2004. The study design would be improved if we had performed 
a randomized prospective study, where neither the gynecological surgeons nor the patients 
would be able to influence the choice of operating method. An improved design would be a 
multicenter study, including a much larger patient cohort, giving us the possibility to match 
the patient operation groups for age, BMI, fertility wishes, and risk for malignancy index 
(RMI). Selecting patients for a prospective operative study for borderline ovarian tumors 
would however include the risk of including some patients with early ovarian invasive 
cancer, as well as women with benign ovarian tumors. The final histological diagnosis of 
BOT is available days or weeks after the operation, after the final formalin-fixed, paraffin- 
embedded sections have been analyzed by a pathologist, and intra-operative frozen section 
diagnosis is often difficult to rely on, especially for the mucinous histology.  
Population used in Papers II-V
In the thesis, biological tissue from 3 different biobanks (A-C, see Chapter 6) was used. In 
Papers II and III, Biobank C includes Israeli biobank sections from Israeli women with 
BOTs. These specimens were obtained through collaboration between Ben Davidson and 
the Sheba Medical Centre, and limited clinical information was available regarding the 
patients. In the Jewish population, the Ashkenazi Jewish carry a BRCA mutation in 1 of 40 
individuals, and up to 40% of ovarian cancer in this population is believed to be of 
hereditary nature (145). In the Norwegian population, BRCA1 mutations seem to be less 
prevalent, about 4% (146). In Norway, BRCA2 mutations have been demonstrated to have 
no significant association with inherited epithelial cancer (147).
Blood sample analyses from Biobank A, the GSI biobank study, were included in Papers IV 
and V. The plasma sampling started January 2003, including women with suspected ovarian 
tumors operated at the Department of Obstetrics and Gynaecology, Ullevål University 
Hospital in this prospective GSI biobank study. The patients signed informed consent, if 
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willing to be recruited. Only 2 of 365 patients have until January 2008 refused to participate 
in the study, when invited. The Biobank includes personal interview with each woman, 
thorough review of the patient’s medical record, preoperative blood sampling, snap freezing 
of tumor tissue, preparation of paraffin blocks of formalin fixed primary tumor and 
metastatic tissue, and collection of ascites and pleura effusions, if present. We believe that 
the recruited patients are representative of all patients operated at the Department, as only 
random PhD/technician availability on regular working days is affecting the capacity to 
include all patients operated.  
As for the recruited population representing the general population of the Oslo area, our 
study may tend to over-represent women with BOT and benign tumors and under-represent 
women with advanced ovarian cancer. In Norway, there is a principle of free patient choice 
of which hospital to be treated at. In emergency settings, and for most patients in practice, 
the local or regional hospital will be the one to serve the patient. Ullevål University Hospital 
is the largest hospital in Norway and the Department of Obstetrics and Gynaecology serves 
as a local hospital for Oslo patients as well as serving as a regional gynecological oncology 
unit for the Regional Health Authority of Eastern Norway (until June 2007). The Norwegian 
Radium Hospital (now part of the Rikshospitalet Medical Center) served as the regional 
gynecological oncology unit for the Regional Health Authority of Southern Norway (until 
June 2007). Women with obvious ovarian cancer, when examined by gynecology specialists 
outside hospital, tend to get referred to the Norwegian Radium Hospital. This center does 
not serve as a local hospital and does not treat women with benign ovarian pathology. 
Table 2 shows the number of patients included in the GSI biobank at Ullevål University 
Hospital each year (and the percentage of women included in the GSI biobank of the total 
amount of women operated at Ullevål University Hospital for the same diagnoses). Table 2 
also shows the number of patients operated at the Norwegian Radium Hospital in the same 
period.
As seen from Table 2, 87% of all women operated for BOT were included in the GSI 
biobank study at UUS in 2004, 67% were included in 2003, whereas only 14% were 
recruited in 2005 (when the PhD student EØ was primarily performing IHC and not 
recruiting study patients). 
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 N= patients operated 2003 2004 2005 2006
Ullevål University Hospital
(GSI, % included of all operated) 
BOT
Invasive epithelial ovarian carcinomas
12/18 (67%)
24/37 (65%)
20/ 23 (87%)
39/55 (71%)
3/22 (14%) 
15/42 (36%) 
6/19 (32%) 
22/64 (34%) 
Norwegian Radium Hospital 
BOT
Invasive epithelial ovarian carcinomas 
28
176
29
199
22
162
24
156
Norway 
BOT
Invasive epithelial ovarian carcinomas 
176
381
176
416
168
385
155
400
Table 2: The numbers of women operated for BOTs and invasive carcinomas at Ullevål 
University Hospital, at the Norwegian Radium Hospital and in Norway between 2003-2006 
(Norwegian Cancer Registry).
Histological reevaluation of the diagnoses 
All tumors used in this thesis were histologically reevaluated by one or two senior 
pathologists. In Papers I, IV and V, a senior pathologist at Ullevål University Hospital, 
Vibeke Engh, reevaluated all included malignant and borderline tumors. In Paper I, all 
benign cysts and tumors operated in this period (January 2000 to December 2004) were also 
reevaluated by Engh. In Paper I, only 3 of 603 histological diagnoses were reclassified 
following reevaluation. In a large population-based study from another health region in 
Norway during a 10-year period, the accuracy of the ovarian cancer diagnosis (without BOT 
included) was estimated as 92%, when reevaluated by a senior pathologist (in 591 patients 
primarily diagnosed histologically with ovarian cancer) (148). Stalsberg et al. published a 
study in 1988, reviewing 869 tumors primarily diagnosed as malignant or BOT, as reported 
to the Cancer Registry of Norway from different hospitals in Norway. The histological 
slides were randomly distributed to six pathologists and classified according to the WHO 
classification of ovarian tumors, demonstrating a mean intra-observer reproducibility of 
62%. The most common disagreement was in identifying the specific type of carcinoma, 
differentiating between undifferentiated and differentiated carcinomas as well as between 
borderline and malignant tumors. Very low reproducibility was obtained for diagnosing 
mixed and unclassified carcinomas (149).  
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In the present thesis, all specimens used were reevaluated by senior pathologists who are 
specialists in gynecopathology, including Vera Abeler and Ben Davidson for Biobank B and 
C (Papers II, III, IV and V), whereas Vibeke Engh reevaluated specimens from Biobank A 
(Papers IV and V) and tumors from women included in Paper I. 
Long-term follow-up
In the retrospective borderline study (Paper I), we were not able to do any long-term follow-
up because the women were recently operated (January 2000 to December 2004). If we had 
included women operated twenty years ago, long-term follow-up would have been possible, 
but laparoscopic advanced surgery was not an option at that time. Patients with BOTs have 
an excellent prognosis (150), and therefore the observation time in this study is too short to 
conclude regarding long-term aspects. Long-term follow-up was also not possible for 
women included in Papers IV and V, as the prospective GSI study has a short observation 
time, including women in the study from January 2003 to December 2006. 
Controls
In Papers IV and V, the selection of control patients could be questioned, comprising 
women being operated for benign ovarian masses. We believe that this is a relevant clinical 
group to include as controls in our study, rather than using a group of healthy women 
without ovarian tumor. Preoperatively, for a woman presenting with an adnexal tumor, a 
blood-based biomarker would be helpful in discriminating between benign ovarian tumors, 
BOT and invasive ovarian cancer, in addition to the clinical and ultrasound findings. In the 
evaluation of endoglin and calprotectin as potential biomarkers in effusions (ascites and 
pleural effusions), we included no benign controls. Benign ovarian tumors very seldom 
produce effusions, compared to advanced-stage ovarian cancer, where the metastatic spread 
often is by excessive effusion production by cancer cells.
8.2 Methodological considerations 
Specific antibodies are indispensable tools when investigating protein expression in tissue 
and effusions. Immunohistochemistry (IHC) is simple and is part of the armament of 
clinical pathology laboratories. Our aim was to investigate potential early markers of 
ovarian cancer, as well as potential prognostic markers in advanced-stage disease (Papers II 
and III). IHC may differ between laboratories as function of different procedures, different 
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antibodies, different staining protocols and different scoring systems. In Paper II we 
therefore additionally performed immunoblotting as a validation method. In Paper III only 
immunohistochemistry was performed for protein assessment, as immunoblotting had been 
done on a part of this material in another study and had already shown strong p-TrkA 
expression.
In Papers IV and V we used ELISA to analyze the calprotectin and endoglin proteins both in 
the circulation (plasma) and in effusions (ascites/pleural effusions). We could have used 
other methods such as immunoblotting to confirm the results, giving additional information 
on protein size detected, but Western blot is more time consuming and less reproducible 
quantitatively than commercially available ELISA. Other investigators (151) and our group 
at Ullevål University Hospital (152) have previously used the same soluble endoglin kit 
used in Paper V, detecting high concentrations of sEng. The cell-bound endoglin (CD 105) 
protein has also been detected by immunohistochemistry in ovarian cancer in a study by 
Taskiran (141). Calprotectin has been found elevated in plasma from patients with several 
cancer forms, including colorectal cancer (134), using the same ELISA method as in this 
thesis (Papers IV and V).
8.3 Sample size calculations  
We did not perform detailed sample size analyzes prior to the start of the different studies, 
as relevant data on the investigated proteins in the tumor tissue (Papers II and III) or in the 
circulation (Papers IV and V) were lacking, and therefore no standard deviations were 
available. The studies in this thesis could therefore be considered as pilot studies. In future 
studies, our results could be used for calculations of sample size. 
In our studies, a too small sample size is especially relevant for the very small FIGO stage I 
group (n=10) included in Papers IV and V. Both type I (false positive result) and type II 
error (false negative result) may occur when including small populations. Also, we 
performed multiple statistical tests in all papers (Papers I-V). We could have performed a 
statistical correction, such as Bonferroni’s correction, to reduce the risk of type I error. This 
was done in Paper V (see comments section), and almost all differences between groups 
remained statistically significant.  
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8.4 Interpretation of the results
Paper I: Laparoscopy versus laparotomy surgery in borderline tumors of the ovary
There is agreement on surgical removal of BOT as the cornerstone in the management of 
this tumor. Over the last decades, the management of BOT has changed from radical 
surgery to more conservative therapy, with more focus on the excellent prognosis for most 
BOT patients, and focus on preservation of fertility for younger women with BOT. There 
have been improvements and increasing use of laparoscopy in surgery in general, as well as 
in oncological surgery.
In our study (Paper I), intraoperative tumor rupture was significantly higher when the tumor 
diameter exceeded 10 cm in diameter. Neither this study (Paper I) nor others previously 
reported (154;155) can conclude at which precise tumor size cut-off a laparotomy approach 
is recommended prior to laparoscopy for a malignant suspected tumor. Conservative surgery 
for stage I BOT with complete staging, including preservation of the uterus and at least one 
or a part of the ovary to preserve fertility, is reviewed in an article by Cadron et al. (15). 
Conservative surgery for stage I BOT is regarded safe, providing long-time follow-up with 
clinical examination and ultrasound. The use of cystectomy, instead of unilateral salphingo-
oophorectomy, has a higher risk of relapse (155;156). In Paper I, the follow-up time is too 
short to conclude whether the choice of operating method has any influence on the 
prognosis. Although laparoscopy is gaining popularity in treatment of BOT, some 
gynecological oncology groups advocate that primary laparotomy is the preferred technique 
(15).
All published studies regarding laparoscopy versus laparotomy in BOT surgical treatment 
are retrospective and not randomized. Prospective randomized studies are needed to 
conclude on effects of surgery type on long-term survival and relapse rates.   
Paper II: The AP-2Ȗ transcription factor
AP-2Ȗ transcription factor is involved in the tumorigenesis of ovarian carcinomas, although 
the exact role is not entirely elucidated. AP-2Ȗ is not expressed in normal ovarian 
epithelium. The expression of nuclear AP-2Ȗ in BOT and stage I carcinomas on tumor level 
is less frequent than in advanced-stage carcinomas. Although we have not explored the 
concentration of this protein in the patients’ circulation in our study (for example using the 
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GSI study samples), we do not believe AP-2Ȗ will have a place as a potential circulating 
marker for early-stage ovarian cancer.  
We found that AP-2Ȗ is expressed in nearly all advanced-stage primary tumors, as well as 
metastatic effusions. Because of its frequent expression we cannot use AP-2Ȗ as a 
prognostic factor in the advanced group. AP-2Ȗ transcription factor is frequently expressed 
both in the primary advanced-stage carcinomas and in the effusions, when the tumor has 
become metastatic. We do not know whether AP-2Ȗ overexpression represents the crucial 
step of tumor metastasis. AP-2Ȗ seems to have a dual role in cell regulation, and AP-2Ȗ may 
contribute to tumor development once compensatory mechanisms are overcome (82;157). It 
is essential to evaluate AP-2 activity and the interacting cofactor network in order to 
highlight the biological role of AP-2 transcription factors in ovarian cancer. Expanded 
knowledge of different AP-2 proteins may offer new strategies for cancer diagnosis and 
management in the future (83).     
Paper III: Nerve growth factor receptors could be a therapeutic target in ovarian 
cancer treatment   
The activated nerve growth factor receptor p-TrkA was selectively expressed in advanced-
stage ovarian carcinomas. We cannot use TrkA or p75 to segregate BOTs from FIGO stage 
I carcinomas by immunohistochemistry, since both tumor types had low expression of these 
receptors. The upregulation of p-TrkA in ovarian carcinomas is specific for the advanced-
stage of disease, when the ovarian carcinoma has become metastatic. This suggests that 
upregulation of p-TrkA is one of the defining steps in tumor progression in ovarian 
carcinomas.            
The generally high MAPK activation in stage I carcinomas and BOTs that we report in 
Paper III is in agreement with other studies in ovarian carcinoma where high MAPK activity 
has been associated with improved prognosis and less aggressive clinical behavior 
(106;108). Downstream targets of TrkA receptor activation may be along the PI3K/AKT 
pathway, which we will evaluate in further studies. 
Since the TrkA receptor is overexpressed in a variety of human tumors and represent a 
marker of poor prognosis, drugs that target this receptor are being developed (158). These 
drugs inhibit autophosphorylation and signaling via Trk family members. CEP-751 may be 
47
a useful therapeutic agent by inhibiting TrkA and inducing tumor apoptosis (158). 
Papers IV and V: Calprotectin in preperative plasma in ovarian neoplasms and in 
effusions from advanced-stage carcinomas 
In Paper IV, the patients were included from 2003 and the short observation time with little 
relapse and survival data makes it too early to evaluate the prognostic impact of plasma 
calprotectin concentrations. Plasma calprotectin was elevated in patients with invasive 
ovarian epithelial cancer, but used as a tumor marker it is inferior to CA 125. In our small 
group of patients with FIGO stage I ovarian cancer (n=15), 60% had elevated CA 125 
(greater than 35 U/mL), as compared to 67% of the patients presenting preoperatively with 
elevated calprotectin plasma concentration (greater than 900 ȝg/L). Further studies are 
warranted, in stage I ovarian cancer disease, to assess whether calprotectin may serve as one 
of several biomarkers in a panel to improve preoperative diagnostics.
In Paper V, calprotectin was explored in 164 effusions from women with advanced-stage 
ovarian carcinomas. The concentration did not correlate with histology grade, FIGO stage or 
survival in advanced-stage ovarian cancer in effusions. Therefore, the clinical value of 
calprotectin effusion concentrations is at present unknown. 
Paper V: Soluble endoglin 
The exact mechanism for sEng formation is unknown. Although sEng correlates with 
metastatic disease in women with breast cancer (144), Paper V did not demonstrate a role 
for plasma endoglin in preoperative discrimination between benign and malignant ovarian 
disease in women presenting with adnexal tumor. Endoglin in effusions from women with 
advanced-stages of epithelial ovarian cancer did not correlate with survival or relapses in the 
patient cohorts.
Although we could not demonstrate a diagnostic preoperative role of plasma sEng in women 
with ovarian tumors, endoglin could bee explored as a biomarker for assessing effects of 
future antioangiogenic therapy in ovarian cancer (140;159). 
48
9. CONCLUSIONS
1. Histological misclassification was very rare in the group of women operated for ovarian 
cysts and tumors at our Department of Obstetrics and Gynaecology (3 of 608 women being 
reclassified, Paper I). Our retrospective study showed that laparoscopic treatment of stage I 
BOTs compared to laparotomy is associated with fewer complications and shorter hospital 
stay. We also found that a BOT size exceeding 10 cm in diameter more often resulted in 
tumor rupture when using laparoscopic versus laparotomy approach (Paper I). Our 
retrospective study cannot conclude at which precise cut-off in tumor size laparoscopic 
versus laparotomy approach should be recommended in early-stage malignant suspect 
ovarian tumors. Peroperative tumor spilling can be reduced with the use of an endobag, and 
the bag size as compared to tumor size is one of the limiting factors to the laparoscopic 
approach, in addition to surgical expertise. Long-term follow-up of larger patient cohorts is 
necessary to determine the ultimate clinical outcome, especially after peroperative tumor 
rupture and spilling.
2. The transcription factor AP-2Ȗ is immunohistochemically localized to the nucleus in 
ovarian BOTs and ovarian carcinomas, but not in the ovarian surface epithelium in normal 
ovaries (Paper II). AP-2Ȗ expression is independent of the presence of the tyrosine kinase 
receptor c-kit in advanced-stage carcinoma. AP-2Ȗ protein expression does not differ 
between BOT and FIGO stage I carcinomas. As protein expression of AP-2Ȗ was 
significantly upregulated in advanced-stage tumors and effusions from stage III-IV 
carcinomas compared to stage I carcinomas, we suggest that this transcription factor is 
involved in tumor progression in ovarian cancer. AP-2Ȗ protein expression did not predict 
survival in advanced-stage disease, and this may be related to its frequent expression (83%) 
in advanced-stage carcinomas (primary tumors, solid metastases and effusions).  
3. The activated nerve growth factor receptor p-TrkA was selectively expressed in 
advanced-stage ovarian epithelial cancer (Paper III). p75 does not seem to be involved in 
tumor progression of ovarian carcinomas. The up-regulation of p-TrkA in advanced-stage 
disease of ovarian cancer could suggest that targeting this receptor may have therapeutic 
value for patients with advanced-stage ovarian disease.  
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4. MAPK activation is independent of p-TrkA and p75 expression in both BOTs and 
invasive carcinomas of the ovary, and we suggest that NGF receptors may signal via 
MAPK-independent pathways in ovarian carcinomas (Paper III). The downstream targets of 
p-TrkA and p75 receptors therefore remain to be identified, but we are currently evaluating 
the role of p-AKT in this setting. p75 appear to have no significant role in ovarian cancer 
biology or disease progression. 
5. Plasma calprotectin concentration is elevated in women with invasive ovarian cancer 
compared to women with benign ovarian tumors and BOT, but the two latter groups do not 
differ in median plasma calprotectin concentrations (Paper IV). This study was too small to 
conclude whether calprotectin could represent an improved plasma-based biomarker for 
early-stage invasive carcinoma. In our patient population, calprotectin was slightly inferior 
to CA 125 in preoperatively differentiating between benign and malignant ovarian disease 
(Paper IV). Calprotectin concentration in effusions does not seem to have a predicting role 
for survival in advanced-stage ovarian carcinoma (Paper V). 
6. Circulating endoglin is not elevated in advanced-stage ovarian carcinoma, in contrast to 
the situation in breast and gastric cancer (Paper V). Plasma endoglin concentration did not 
preoperatively discriminate between benign and malignant ovarian tumors in our study 
population. Also, effusion endoglin concentration does not seem to be related to survival in 
advanced-stage ovarian carcinoma.  
More knowledge about signaling pathways in the malignant transformation in ovarian 
tumors is important in an era of targeted therapies. New biomarkers could be used for early 
detection of epithelial ovarian cancer, which is urgently needed to detect ovarian cancer at 
an earlier stage of the disease. Markers to validate treatment effects and to aid 
individualizing cancer treatment are warranted. Epithelial ovarian neoplasia comprises a 
heterogeneous group of tumors. There is no identified precursor lesion for ovarian cancer, 
and there is a lack of comprehensive tumor progression model. Our studies may have 
contributed to identify some small pieces of the enormous puzzle and enigma of ovarian 
carcinoma, a disease that deprives too many women of too many years of life.   
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10. FURTHER STUDIES 
1. More biomarker studies on women with ovarian carcinoma, coupled to clinical data 
and survival 
Our GSI biobank included by January 2008 biological samples and clinical information 
from more than 365 women. In addition to comprehensive clinical information, we have 
sampled preoperative blood samples, snap frozen (in liquid nitrogen) biopsies during 
surgery from the tumor and/or metastases as well as provided corresponding paraffin block 
from the same tumor. All biological samples have been carefully sampled and stored in a 
standardized way. The women included in the study have also given our research group at 
UUS the permission to follow them through hospital and death registries, and, if alive, to 
contact them again asking for participation in further research projects. This biobank 
enables several future projects, including studies on protein, mRNA as well as DNA levels. 
When looking at gene and protein expression from the same patients in different 
compartments (tumor, metastases, effusions, blood cells, serum/protein), we hope to identify 
new biomarkers, or combinations of such. Such new biomarkers may prove useful in 
identifying women with ovarian cancer as well as clinically segregate women with ovarian 
cancer into different prognostic and treatment modality groups.  
2. Long-term survival of BOT patients according to surgical approach 
Our Department of Obstetrics and Gynaecology treat surgically many women with BOT by 
laparoscopy. Women with BOT have an overall good prognosis. Longer observation time 
and systematic collecting of clinical findings would allow us in the future to evaluate the 
long-term effect of tumor spilling in the laparoscopic versus laparotomy approach on 
recurrence of disease. All BOT patients included in Paper I have signed informed consent to 
be followed clinically, also through other hospital and the Death and Cancer registries in 
Norway.
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11. ERRATA
Paper I:
-Page 622:  “All patients signed informed consents: Should read: “All BOT patients 
signed an informed consent…” 
- Page 621: RMI has a reference number 7. The correct reference is number 8 
(Tingulstad et al.) 
Paper II:
- Page 463: Anttila et al. is correct, not Antilla et al. 
- Page 464: Figure 1 text: Figure F, not E has a normal fallopian tube in the lower 
right corner 
- Page 465: Table 2 heading: the study material consists of 403 specimens, not cases. 
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